Vraylar (cariprazine) stays in your system far longer than most medications. After your last dose, the drug and its active byproducts take roughly 2 to 3 months to fully clear from your body. This unusually long timeline is driven by one of its breakdown products, which has an estimated half-life of 1 to 3 weeks.
Why Vraylar Lingers So Long
Most drugs are processed into inactive waste products that your body flushes out. Vraylar is different. Your liver breaks cariprazine (the parent drug) into two active metabolites that continue working in your body just as the original drug did. The first metabolite clears relatively quickly. The second one, called DDCAR, accumulates in your system and takes weeks to disappear.
Here’s how the half-lives break down:
- Cariprazine (the parent drug): 2 to 4 days
- First metabolite (DCAR): 1 to 2 days
- Second metabolite (DDCAR): 1 to 3 weeks
A half-life is the time it takes for half the substance to leave your bloodstream. It typically takes 4 to 5 half-lives for a drug to be considered fully eliminated. With DDCAR’s half-life stretching up to 3 weeks, that math puts the total clearance window at roughly 2 to 3 months. FDA testing confirmed that after even a single 1 mg dose, DDCAR was still detectable 8 weeks later.
What Happens Week by Week After Stopping
The parent drug and first metabolite drop off quickly. Within about one day of your last dose, cariprazine and DCAR levels fall by roughly 50%. By the end of the first week, both are down by about 90%.
DDCAR is the slow one. Its levels drop by about 50% in the first week, then take approximately 4 weeks total to decline by 90%. This is why the FDA notes that changes in your clinical symptoms may not immediately match the decline in your dose. The medication is still pharmacologically active in your body for weeks after you stop taking it, which can be either a benefit (smoother transition) or a concern (lingering side effects) depending on your situation.
How Your Body Eliminates Vraylar
Your body clears Vraylar through both the kidneys and the liver, with the liver doing more of the heavy lifting. In clinical studies, about 46% of each daily dose was excreted through feces and 24% through urine. Only about 5% left the body as unchanged cariprazine. The vast majority was excreted as metabolites, meaning your liver does significant processing before the drug is eliminated.
The primary enzyme responsible for breaking down cariprazine is CYP3A4, with a smaller contribution from CYP2D6. This matters because other medications that affect CYP3A4 activity can change how long Vraylar stays in your system.
What Can Slow Elimination
Certain medications interfere with the liver enzyme that processes Vraylar, effectively putting the brakes on clearance. Strong CYP3A4 inhibitors (like ketoconazole, an antifungal) doubled the total drug exposure in studies and are contraindicated with Vraylar in many countries. Moderate inhibitors like erythromycin, fluconazole, diltiazem, and verapamil increased exposure by 40 to 50%, which could meaningfully extend the time the drug stays active in your system.
Interestingly, genetic differences in CYP2D6 (the secondary processing enzyme) don’t appear to make a meaningful difference. Studies found no substantial effect on cariprazine levels based on whether someone was a fast or slow CYP2D6 metabolizer. Kidney function also doesn’t significantly change how quickly Vraylar clears, since the liver handles most of the processing.
Vraylar and Drug Testing
Standard drug screening panels (the 5-panel and 12-panel tests used by employers) test for substances like amphetamines, opioids, cannabis, cocaine, and benzodiazepines. Vraylar is not in any of these categories and will not trigger a positive result on standard screening.
Specialized antipsychotic urine panels do exist, but even these typically test for older medications like haloperidol, clozapine, and chlorpromazine. Cariprazine is not included on standard antipsychotic drug profiles. The only way Vraylar would show up is through a test specifically designed to detect it, which is uncommon outside of clinical research settings.
Practical Timeline Summary
If you’re discontinuing Vraylar, the realistic timeline looks like this: within the first week, the parent drug is largely gone from your bloodstream. By 4 weeks, around 90% of all active compounds, including the long-lasting metabolite, have cleared. Full elimination to undetectable levels takes approximately 2 to 3 months. During this extended washout period, the medication can still influence your brain chemistry, so both therapeutic effects and side effects may persist well beyond your last pill.